Informing MS patients on treatment options: a consensus on the process of consent taking
- Autori: Tortorella C.; Solaro C.; Annovazzi P.; Boffa L.; Buscarinu M.C.; Buttari F.; Calabrese M.; Cavalla P.; Cocco E.; Cordioli C.; De Luca G.; Di Filippo M.; Fantozzi R.; Ferraro D.; Gajofatto A.; Gallo A.; Lanzillo R.; Laroni A.; Fermo S.L.; Malucchi S.; Maniscalco G.T.; Moccia M.; Nociti V.; Paolicelli D.; Pesci I.; Prosperini L.; Ragonese P.; Tomassini V.; Clerici V.L.A.T.; Rodegher M.; Gherardi M.; Gasperini C.
- Anno di pubblicazione: 2020
- Tipologia: Articolo in rivista
- OA Link: http://hdl.handle.net/10447/424333
Abstract
Abstract: In the last years, change in multiple sclerosis (MS) therapeutic scenario has highlighted the need for an improved doctor-patient communication in advance of treatment initiation in order to allow patient’s empowerment in the decision-making process. Aims: The aims of our project were to review the strategies used by Italian MS specialists to inform patients about treatment options and to design a multicentre shared document that homogenizes the information about disease-modifying treatment (DMTs) and the procedure of taking informed consent in clinical practice. Results: The new resource, obtained by consensus among 31 neurologists from 27 MS Centres in Italy with the supervision of a medico-legal advisor, received the aegis of Italian Neurological Society (SIN) and constitutes a step toward a standardized decision process around DMTs in MS.